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ABSTRACT 
Background. In idiopathic pulmonary arterial hypertension (IPAH) treatment goals include improving 
right ventricular (RV) function, hemodynamics and symptoms to move patients to a low risk category 
for adverse clinical outcomes. No data are available on the effect of upfront combination therapy on 
RV improvement, compared with monotherapy. The aim of the present study is to evaluate 
echocardiographic RV morphology and function in patients affected by IPAH treated with different 
strategies. 
Methods. Sixty-nine consecutive treatment-naive IPAH patients treated with first-line upfront 
combination therapy at 10 centers were retrospectively evaluated and compared with two matched 
cohorts treated with monotherapy after short-term follow-up. Evaluation included clinical, 
hemodynamic and echocardiographic parameters. 
Results. After 155±65 days from baseline evaluation, patients in the oral+prostanoid group (Group 
1) experienced the most important clinical and hemodynamic improvement compared with the 
double oral group (Group 2), the oral monotherapy group (Group 3) and the prostanoid monotherapy 
group (Group 4). The more extensive reduction of pulmonary vascular resistance in Group 1, 2 and 
4 was associated with a significant improvement in all RV echocardiographic parameters compared 
with Group 3. Considering the number of patients who reached the target-goals suggested by 
guidelines, 8/27 (29.6%) and 7/42 (16.7%) patients in Group 1 and 2, respectively, achieved low risk 
status compared with 2/69 (2.8%) and 6/27 (22.2%) in Group 3 and 4, respectively. 
Conclusions. In advanced treatment-naïve IPAH patients, an upfront combination therapy strategy 
seems to significantly improve hemodynamics and RV morphology and function compared with 
oral monotherapy. The most significant results seem to be achieved with prostanoids plus oral 
drug, while double oral combination and prostanoids as monotherapy seem to produce similar 
results. 
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ABBREVIATIONS LIST 
 
6MWT: 6-minute walk test 
CI: cardiac index 
CO: cardiac output 
ERA: endothelin receptor antagonists  
IPAH: idiopathic pulmonary arterial hypertension  
LV: left ventricular 
LV-EId: left ventricular diastolic eccentricity index 
LV-EIs: left ventricular systolic eccentricity index 
mPAP: mean pulmonary artery pressure 
MRI: magnetic resonance imaging 
PAH: pulmonary arterial hypertension  
PDE5i: phosphodiesterase-5 inhibitors  
PVR: pulmonary vascular resistance 
PWP: pulmonary wedge pressure 
RA: right atrium 
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RAP: right atrial pressure 
RHC: right heart catheterization 
RV: right ventricular 
RVEDA: RV end-diastolic area 
RVESA: RV end-systolic area 
RVFAC: RV fractional area change  
TAPSE: tricuspid annular plane systolic excursion 
WHO: World Health Organization 
INTRODUCTION 
Idiopathic pulmonary arterial hypertension (IPAH) is a rare disease characterized by a progressive 
increase of pulmonary vascular resistance (PVR) leading to right heart failure.1,2 Although the 
prognosis of IPAH has improved in the last decade, we are far from a cure, with long term morbi-
mortality rates still unsatisfactory. At diagnosis, the majority of treatment-naïve patients present at 
intermediate risk of clinical worsening or death.3 Right ventricular (RV) maladaptation to increased 
afterload represents the main determinant of patients’ prognosis and is characterized over time by 
an increase in RV dimensions and a decrease in systolic function.4,5 New guidelines suggest two 
alternative approaches for intermediate-risk patients, leaving it up the clinician’s discretion whether 
to initiate traditional monotherapy or an upfront combination therapy to these patients.3 No data are 
available on the effect of an upfront combination therapy strategy on RV morphological and 
functional improvement, compared with monotherapy especially when considering parenteral 
prostanoids in the upfront combination strategy. Furthermore, no data are available comparing the 
two different approaches in achieving the target-goals suggested by guidelines. 
5 
 
The present study tried to approach this problem evaluating the hemodynamic profile and RV 
improvement, assessed by echocardiography, in treatment-naïve IPAH patients with two different 
approaches: monotherapy compared with upfront combination therapy, including parenteral 
prostanoid as a possible upfront combination. 
METHODS 
Study population  
The study retrospectively evaluated 69 consecutive treatment-naive IPAH patients followed at nine 
centers from the italian Pulmonary Hypertension NETwork (iPHNET) and one center from the 
United States (Allegheny General Hospital, Pittsburgh, Pennsylvania), between January 2011 and 
July 2015 and treated with first-line upfront combination therapy. The choice of specific drugs used 
in upfront combination was based on the usual clinical practice at each center and included 
endothelin receptor antagonists (ERA), phosphodiesterase-5 inhibitors (PDE5i) and parenteral 
prostanoids. Titration regimen of parenteral prostanoid was based on patient’s tolerance and all 
centers were compliant with the concept of high dosage to reach significant effects.  Upfront 
combination therapy was defined as two drugs from different classes initiated within three weeks of 
each other and maintained throughout the duration of the study period. Similar therapeutic 
strategies have been evolved during the years in the same way in each center as this group meets 
periodically in regional and national meetings. All centers had a common follow-up strategy 
according to the suggested assessment and timing highlighted by ESC/ERS Guidelines.3 
The diagnosis of IPAH was defined and confirmed according to the recent European guidelines3 to 
exclude secondary causes and conforming to the hemodynamic profile showing precapillary 
pulmonary hypertension (mean pulmonary artery pressure-mPAP ≥ 25 mmHg, pulmonary wedge 
pressure-PWP <15 mmHg, pulmonary vascular resistance-PVR >240 dynes*s*cm-5). 
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Baseline evaluation included medical history, physical examination, a non-encouraged 6-minute 
walk test (6MWT), right heart catheterization (RHC) and echocardiographic assessment.  
Patients with an acute vasodilator response at the time of diagnosis were excluded.  
Patients’ risk assessment was defined as low, intermediate and high according to most of the 
variables suggested by the current guidelines (3): intermediate risk for WHO functional class III, 
6MWT 165-440m, right atrial pressure-RAP 8-14mmHg, cardiac index-CI 2.0-2.4 l/min/m2, right 
atrial area 18-26 cm2, and no or minimal pericardial effusion; low and high risk, below and above 
the previous values, respectively.  
A historical group of 69 treatment-naive IPAH patients matched for age, gender, WHO functional 
class, 6MWT and hemodynamic baseline parameters, treated with oral monotherapy before 2012 
was used for comparative analysis and selected from all centers. International guidelines available 
at that time6 were less insistent on earlier combinations of drugs and parenteral prostanoids 
utilization than their 2015 update. 
Another historical group of 27 treatment-naive matched IPAH patients treated with parenteral 
prostanoid before 2012 was used for comparative analysis to exclude that parenteral prostanoids 
per se could explain the results observed in the upfront combination group.  
This retrospective study complies with the Declaration of Helsinki and was approved by the local 
Institutional Review Boards for human studies of each center (Protocol n. 42412 for Europe; 
Protocol RC-5841 for USA). 
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Right heart catheterization  
Hemodynamic evaluation was made with standard technique. Pressures were measured from the 
mid-chest position with a fluid-filled catheter and pressure transducer, recording the average 
values over three respiratory cycles, according to a common protocol highlighted by guidelines.3 
Cardiac output (CO) was measured by the thermodilution technique (American Edwards 
Laboratories, Santa Ana, CA) and pulmonary vascular resistance (PVR) was calculated with the 
formula PVR=(mPAP-PWP)/CO.  
 
Echocardiographic assessment  
The most common standard-practice echo-parameters used in diagnostic work-up and follow-up of 
PAH patients have been evaluated in the present study. 
Baseline echocardiographic studies were performed 1 week from RHC, before starting specific 
treatment. All echocardiographic data were acquired by dedicated operators, with the patient in the 
left lateral decubitus position using commercially available equipment. Standard M-mode, 2D and 
Doppler images were obtained during breath hold at end expiration and measurements were 
obtained from the mean of 3 consecutive beats in accordance with the American Society of 
Echocardiography Guidelines.7 The echocardiograms were read retrospectively specifically for this 
study and all centers participating to the study were compliant to international guidelines.6 The 
following standard parameters and derived measures were considered in the analysis: right atrial 
area (RA area), RV end-diastolic area (RVEDA), RV end-systolic area (RVESA), RV fractional 
area change % [RVFAC=(RVEDA - RVESA)/RVEDA x 100], tricuspid annular plane systolic 
excursion (TAPSE), left ventricular systolic and diastolic eccentricity index (LV-EIs and LV-EId, 
respectively), and presence of pericardial effusion. Tricuspid regurgitation was semiquantitatively 
graded considering the regurgitant jet area at color Doppler imaging. The transmitral flow velocity 
8 
 
curve was obtained by pulsed Doppler imaging, positioning the sample volume between the tips of 
the mitral leaflets. E- and A-wave peak velocities, and the ratio of early transmitral flow velocity to 
atrial flow velocity were measured. 
Three centers were randomly selected for variability evaluation and the widest values reported in 
the study. Intraobserver and interobserver variability are reported as following: RVEDA 
intraobserver 0.18 ± 0.66 (95% confidence interval [CI]: -1.09 to 1.45), interobserver 0.15 ± 1.08 
(95% confidence interval [CI]: -2.07 to 2.37); RVESA intraobserver 0.16 ± 0.50 (95% confidence 
interval [CI]: -0.77 to 1.09), interobserver 0.05 ± 0.55 (95% confidence interval [CI]: -1.10 to 1.20); 
LV-EId intraobserver 0.00 ± 0.07 (95% confidence interval [CI]: -0.13 to 0.13), interobserver -0.02 
± 0.08 (95% CI: -0.18 to 0.14); LV-EIs intraobserver -0.01± 0.04 (95% confidence interval [CI]: -
0.06 to 0.04), interobserver 0.01 ± 0.11 (95% CI: -0.18 to 0.20); RA area intraobserver 0.01 ± 0.44 
(95% confidence interval [CI]: -0.86 to 0.88), interobserver 0.22 ± 1.07 (95% CI: –1.62 to 2.06); 
TAPSE intraobserver 0.20 ± 0.63 (95% confidence interval [CI]: -1.03 to 1.43), interobserver 0.00 ± 
0.67 (95% CI: -1.06 to 1.06); LVEDA intraobserver 0.06 ± 0.79 (95% confidence interval [CI]: -1.52 
to 1.64), interobserver -0.07 ± 0.76 (95% confidence interval [CI]: -1.63 to 1.49); LVESA 
intraobserver -0.02 ± 1.32 (95% confidence interval [CI]: -0.67 to 0.63), interobserver 0.04 ± 0.42 
(95% confidence interval [CI]: -0.79 to 0.87). 
Statistical analysis  
To compensate for the lack of randomization methods, the Nearest Neighbor matching method 
1:1, by the exact distance, was used to balance the distribution of covariates in the upfront-treated 
and control groups, diagnosing the quality of the resulting matching through the standardized 
difference in means (the difference in means of each covariate divided by the standard deviation in 
the full treated group). This method was chosen as the most effective method (increased power 
and decreased bias) for small groups sizes.8 
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Continuous data are expressed as mean ± standard deviation, and categorical data are expressed 
as counts and proportions. Two-group comparisons were done with unpaired or paired, two-tailed t 
tests for means if the data were normally distributed or with Wilcoxon’s rank-sum tests if the data 
were not normally distributed. Comparisons among disease group were made by using two-way 
analysis of variance (ANOVA). If significant differences were found, post-hoc comparisons 
(Duncan’s multiple range test, Scheffé test) were used to determine the statistical significance 
among groups. Chi square or Fisher’s exact tests were used to analyze the categorical data.  
Linear regression analysis was performed to assess the relations between RVEDA, RVFAC and 
PVR and expressed as a Pearson correlation coefficient. 
Intraobserver and interobserver variability has been measured by the Bland-Altman method by 
three clinicians from three different centers and has been assessed in a randomly selected cohort 
of 10 patients. The widest values have been reported in the text.  
All statistical analyses were performed using SPSS software (version 20.0, IBM) and Stata 13 
(StataCorp, College Station, TX, USA). All statistical tests were 2-sided, and a p value <0.05 was 
considered statistically significant. 
 
RESULTS  
Study population 
Sixty-nine consecutive treatment-naïve IPAH patients observed at 10 centers were started on 
upfront combination therapy between January 2011 and July 2015, with a mean interval of 8.0 ± 
6.7 months (range 1 to 36 months) between IPAH diagnosis and initiation of symptoms. The 
patients were predominantly females (63.8%) with a mean age of 54 ± 15 years. The majority of 
patients were WHO functional class III at diagnosis, with severe pulmonary hypertension and 
10 
 
impaired functional capacity. The echocardiographic evaluation at baseline was consistent with a 
severe RV dilatation and systolic dysfunction.  
A matched cohort of 69 treatment-naive IPAH patients receiving oral monotherapy (Bosentan, 
n.28, 40.6%; Ambrisentan, n.14, 20.3%; Sildenafil, n.18, 26.1%; Tadalafil, n.9, 13.0%) and a 
second matched cohort of 27 treatment-naive IPAH patients receiving prostanoids as monotherapy 
(Epoprostenol i.v., n. 7, 25.9%; Treprostinil s.c., n. 20, 74.1%) were considered for comparative 
purposes.  
Table 1 summarizes the baseline characteristics of the upfront combination treated-group, divided 
in oral plus parenteral prostanoid (Group 1) and double oral combination (Group 2), and the two 
monotherapy matched cohorts, oral (Group 3) and prostanoids (Group 4). The four groups of 
patients were similar for the demographic, clinical, hemodynamic and echocardiographic profile.  
Short-term follow-up: clinical condition and exercise capacity 
After 155 ± 65 days, all patients in the study experienced a significant improvement in the WHO 
functional class compared to baseline (Table 2 and 3) with improvement to WHO class II in 77.8% 
(21/27; p<0.001) in Group 1, 78.6% (33/42; p<0.001) in Group 2, 52.2% (36/69; p<0.001) in Group 
3 and 77.7% (21/27; p<0.001) in Group 4 (Group 1 vs 2, p=ns; Group 1 vs 3, p=0.03; Group 1 vs 4, 
p=ns; Group 2 vs 3, p=0.01; Group 2 vs 4, p=ns; Group 3 vs 4, p=0.02). 
Similarly, six-minute walk distance significantly improved by 101 ± 52 m (p=0.0001) in Group 1 and 
56 ± 53 m (p=0.0001) in Group 2 compared with a more modest change of 26 ± 48 m (p=0.0001) 
in the oral monotherapy group (Group 1 vs 2, p=0.001; Group 1 vs 3, p=0.001; Group 2 vs 3, 
p=0.007).  
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Interestingly, 6MW distance improved by 48 ± 26 m (p=0.0001) in Group 4, similarly to Group 2 
(Group 1 vs 4, p=0.001; Group 2 vs 4, p=ns; Group 3 vs 4, p=0.004). 
All patients tolerated combination therapies well and none of the patients needed to withdraw the 
treatment regimen. 
 
Short-term follow-up: hemodynamic and RV morphology and function 
All patients underwent an echocardiographic assessment after 155 ± 65 days from the initiation of 
therapy. Invasive hemodynamic data were also available for 136/138 (98.5%) patients.  
Changes in the hemodynamic and echocardiographic parameters from baseline to short-term 
follow-up were compared between Group 1, 2 and 3 (Table 2). Patients in Group 1 experienced 
the greatest hemodynamic improvement overall compared with patients in either Group 2 or Group 
3. For example, although all 3 groups demonstrated a significant reduction in right atrial pressure 
(RAP), Group 1 patients reached a more robust improvement compared to the other patients 
(Group 2 and 3). Similarly, cardiac index (CI) significantly increased in all patients, but patients with 
the upfront combination approach reached a more relevent increase compared with the oral 
monotherapy approach, without reaching significance between Group 1 and 2. Importantly, Group 
1 and Group 2 showed a -50% and -39.8% reduction of PVR, respectively, compared with -14.7% 
reduction in Group 3.  
The mean dosage of prostanoid reached at 155 ± 65 days in Group 1 was 36 ± 14 ng/kg/min 
(range 15-56 ng/kg/min) with epoprostenol i.v. and 42 ± 10 ng/kg/min with treprostinil s.c. (range 
14-58 ng/kg/min). Importantly, none of the patients treated with upfront combination therapy 
developed a hemodynamic and clinical pattern of high output cardiac failure. 
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Interestingly, the hemodynamic improvement experienced by Group 4 was similar to Group 2, with 
– 3.3 ± 3.9 mmHg reduction in RAP (Group 1 vs 4, p=ns; Group 2 vs 4, p=ns; Group 3 vs 4, 
p=0.001), + 0.58 ± 0.42 l/min/m2 increase in CI (Group 1 vs 4, p=ns; Group 2 vs 4, p=ns; Group 3 
vs 4, p=0.002), and – 5.2 ± 1.2 WU (-38.4%) reduction in PVR (Group 1 vs 4, p=0.02; Group 2 vs 
4, p=ns; Group 3 vs 4, p=0.001). These results were reached with a mean dosage of 34 ± 12 
ng/kg/min for epoprostenol i.v. (range 16-52 ng/kg/min) and 40 ± 8 ng/kg/min for treprostinil s.c 
(range 15-56 ng/kg/min). 
The more extensive reduction of PVR in Group 1 and 2 was associated with a significant 
improvements in all morphological and functional echocardiographic parameters compared with 
Group 3. Figures 1 and 2 reflect the relationship between RV morphological (RVEDA) and 
functional changes (RVFAC) with respect to afterload reduction (PVR). Treatment effects are 
clearly clustered following their management strategies. Patients treated with the upfront 
combination strategy (Group 1 and 2) and with prostanoid monotherapy (Group 4) are clustered to 
the bottom left (Figure 1) and upper left (Figure 2) of the remodeling/PVR relationship, indicating a 
significant improvement in RV morphology and function. Conversely, those patients treated with 
the oral monotherapy approach (Group 3) remain around the middle indicating poor improvement 
in RV conditions. Group 4 patients showed a significant improvement in right heart morphological 
and functional parameters similar to Group 2 and significantly less pronounced than Group 1 
(Table 3). Figure 3 shows an example of significant right heart morphological and functional 
improvement in a patient treated with upfront combination therapy (Group 1). 
RVFAC was chosen over TAPSE for systolic function description as allows a more clear and 
continuous distribution of patients in respect of afterload, not presenting a floor effect in case of 
severe RV dysfunction9 and the influence by the overall heart motion.10 
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Therapeutic strategy and risk profile 
We analyzed the effect of different strategies, upfront combination compared with monotherapy, in 
achieveing the low-risk clinical profile, compatible with a good long-term prognosis. Most of the 
variables suggested by the current guidelines were considered for the analysis: WHO functional 
class I/II, 6MW distance > 440 m, RAP < 8 mmHg, CI ≥ 2.5 l/min/m2, RA area < 18 cm2 and the 
absence of pericardial effusion.  
At baseline, 16 (59.3%) and 11 (40.7%) patients in Group 1, 25 (59.5%) and 17 (40.5%) in Group 
2, 51 (73.9%), 18 (26.1%) in Group 3, 15 (55.5%) and 12 (44.4%) in Group 4 had an intermediate 
and high risk profile, respectively (p=ns, between groups).  
Among high risk patients, 8 (72.7%) and 3 (27.3) moved to an intermediate and low risk profile in 
Group 1, respectively; 11 (64.7%) and 5 (29.4%) moved to an intermediate and low risk profile, 
respectively, while 1 (5.9%) remained unchanged in Group 2; 10 (55.6%) unchanged their risk 
profile and 8 (44.4%) moved to an intermediate risk in Group 3; 8 (61.5%) and 4 (30.8%) moved to 
an intermediate and low risk profile, respectively, while 1 (7.7%) remained unchanged in Group 4 
(Group 1 vs 2, p<0.05; Group 1 vs 3, p=0.001; Group 1 vs 4, p<0.05; Group 2 vs 3, p=0.001; 
Group 2 vs 4, p=ns; Group 3 vs 4, p=0.001) (Figure 4).  
Among intermediate risk patients, 11 (68.7%) and 5 (31.3%) in Group 1, 23 (92%) and 2 (8.0%) in 
Group 2, 49 (96%) and 2 (4.0%) in Group 3, 12 (85.7%) and 2 (14.3%) in Group 4, remained 
unchanged and moved to a low risk profile, respectively (Group 1 vs 2, p<0.05; Group 1 vs 3, 
p=0.001; Group 1 vs 4, p<0.05; Group 2 vs 3, p=0.001; Group 2 vs 4, p=ns; Group 3 vs 4, 
p=0.001). 
Interestingly, overall the number of patients who reached those target-goals (clinical, functional 
capacity, hemodynamic and echo-imaging) was 8/27 (29.6%) in Group 1, 7/42 (16.7%) in Group 2 
and 2/69 (2.8%) in Group 3, 6/27 (22.2%) in Group 4 (Figure 5).  
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DISCUSSION 
The present study seems to support the concept that upfront combination therapy may provide 
more pronounced hemodynamic, RV morphological and functional improvement compared with 
the oral monotherapy strategy, suggesting that a combination parenteral prostanoid plus oral drug 
could reach better results than oral combination therapy. This concept is particularly true for 
advanced IPAH patients with an intermediate and high-risk profile at diagnosis, as the current 
study population. 
Our population includes patients with a demographic and clinical profile similar to a typical incident 
IPAH patients, as reported in recent international registries11,12 with severe pulmonary 
hypertension, low CI, advanced WHO functional class and reduced functional capacity. 
In the present study, all treatment strategies were able to improve CI, but the upfront combination 
with prostanoid plus oral drug decreased PVR to a larger extent compared with the other 
strategies. These results are in agreement with the study of Sitbon et al in high-risk PAH patients, 
showing greater improvement in PVR with the upfront combination epoprostenol plus oral drug 
compared with epoprostenol alone.13,14 Notably, the reduction of PVR observed by Sitbon et al 
after 3-4 months of epoprostenol monotherapy was similar to the improvement shown in our Group 
4. Thus, as the main pathophysiologic-driven mechanism for RV dysfunction is represented by 
afterload mismatch, 15 it is not surprising that the treatment strategies associated with more 
pronunced reduction in PVR have reached a significant improvement of all echocardiographic-
derived morphologic and functional parameters, including RA area, LV-EI and pericardial effusion, 
widely known to be of prognostic significance. As a consequence, a greater number of patients 
started on upfront prostanoid plus oral drug achieved a low-risk profile compared with the others. 
Interestingly, patients treated with the upfront double oral combination and those treated with 
prostanoid monotherapy had similar improvement in their risk profile, with an intermediate 
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response between oral monotherapy and prostanoid-combination.  
However, as only 35.7% of patients in the double oral Group followed the Ambrisentan plus 
Tadalafil combination suggested by the AMBITION study,16we cannot exclude a more pronounced 
effect with the latter combination compared with others. On the other hand, as only 52% of patients 
on parenteral prostanoids were combined with PDE5i, whether a substantial additional impact on 
the findings could be possible, as the PACES study would suggest when a PDE5i is associated to 
parenteral prostanoids,17 may not be claimed from the present study. 
A more pronounced improvement in WHO functional class was observed among all treated-
groups, compared with randomized controlled trials18–24 and the AMBITION study.16 Although a 
possible explanation may arise from an interpretation bias on patient’s clinical condition by 
unblinded physicians, we cannot exclude that in a pure afterload mismatch model, as our IPAH 
patients, the hemodynamic improvement may translate more easily in WHO class improvement, in 
agreement with the previous observation of Kemp et al for patients treated with upfront 
combination therapy. Indeed, in randomized controlled trials16,18-24 more than 30% of patients 
enrolled are connective tissue disease related PAH, where the systemic disease may explain the 
mismatch between the hemodynamic and the functional improvement. 
In our study, targeted monotherapy with oral approved drugs, as ERA and PD5i, was able to 
improve WHO functional class and 6-minute walk distance, increase CI and reduce PVR to a 
similar magnitude seen in randomized controlled trials that established the efficacy of those 
treatments.18-24 Nevertheless, our results indicate that only a few patients with this approach were 
able to achieve a recommended target-goal. These is the first report describing patient’s risk profile 
after oral monotherapy and highlights that mild afterload reduction, as observed after 4 to 6 months 
of oral monotherapy, may provide low probability of reversing right heart dilatation and 
substantially improving right vetricular systolic function, thus not significantly changing patient’s 
clinical risk profile. To our knowledge, no previous study based on echocardiographic or magnetic 
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resonance imaging (MRI) evaluation has ever reported a significant improvement of right heart size 
and function after short-term or long-term monotherapy. Indeed, echocardiographic indices have 
been used in substudies of randomized controlled trials, trying to demonstrate improvement of RV 
morphology and function after oral monotherapy. These have shown very small effects on RV end-
diastolic volume, LV-EI and the ratio of RV to LV surface areas.25,26 The EURO-MR prospective 
study 27 reported previously the effects of targeted monotherapies on cardiac MRI-derived indices 
of RV structure and function in PAH patients. The authors did not find significant changes in RV 
volumes and only mild changes in RV ejection fraction, but within the limits of agreement of 
interobserver variability measurements.  
Other single-center studies, based on echocardiographic or MRI evaluation, showed no effect on 
RV volume and ejection fraction after oral monotherapies.28–30 
Recent findings by van de Veerdonk et al31 showed that disease progression and mortality are 
preceded by changes in RV dimensions and decrease in RV systolic function, even in stable 
patients, highlighting the importance of RV imaging evaluation during patients’ follow-up. 
Thus, as the oral monotherapy approach is associated with only limited changes in pulmonary 
hemodynamics and seems unable to significantly improve RV morphological and functional 
parameters in such advanced patients, we cannot exclude that monotherapy although it has 
demonstrated to improve exercise capacity and reduce hospitalization rates in clinical trials, may 
just delay clinical events in the long-term. 
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STUDY LIMITATIONS 
The lack of randomization is the major limitation of the study, as the arbitrary decision on which 
treatment was adopted in the individual patients may have influenced the results (and different 
criteria may have been adopted in different centers). However, as randomization is used to ensure 
balance of the covariates between the treated and control groups, and matching methods are used 
to replicate this as much as possible for observational (nonrandomized) data.8 After all, our results 
in terms of clinical and hemodynamic data are in agreement with those reported by international 
randomized trials, supporting the hypothesis that despite the absence of randomization, the 
matching method used in the present study was acceptable enough for our purposes. Indeed, no 
randomized prospective studies on the effects of different treatment strategies on RV structure and 
function have ever been done, despite the recognized importance of the RV for patients’ 
prognosis. 
A second limitation arises from the absence of a central core lab for echo-measurements. 
Nevertheless, to minimize interobserver variability all centers participating to the study were 
compliant to international guidelines and well known from the literature for echo-studies, allowing 
the adoption of a common protocol (echo guidelines). Three centers were randomly selected for 
interobserver variability evaluation and the widest values reported in the study. This may result in a 
more conservative approach to avoid that a difference between two treatment groups may result 
from interobserver variability instead of different treatment-regimen effects. In this way any 
inaccuracy and imprecision introduced by the measurements were against the upfront treatment 
effects. 
Finally, as all the centers involved in the study were dedicated PH centers, all but 10 patients in the 
upfront combination group, had the complete set of the hemodynamic and echocardiographic data 
recorded. We have repeated the analysis excluding those patients with incomplete data without 
finding different results. 
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CONCLUSIONS 
In treatment-naïve IPAH patients, an upfront combination therapy strategy seems to significantly 
improve hemodynamics and RV morphology and function compared with oral monotherapy. The 
most significant results seem to be achieved with prostanoids plus oral drug, while double oral 
combination and prostanoids as monotherapy seem to produce similar intermediate results. 
Finally, our study suggests that intermediate and high risk patients may result undertreated from 
an oral monotherapy approach.  
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FIGURE LEGENDS 
Figure 1. Correlation between the changes in RVEDA and PVR at short-term follow-up:  ∆ RVEDA 
versus ∆ PVR (quadratic model: r2=0.49, p=0.0001, y=2.6+0.27x-0.0023x2; linear model: r2=0.48, 
p=0.0001, y=3.43+0.40x). Patients treated with oral monotherapy, prostanoid monotherapy, 
upfront oral combination and upfront oral plus prostanoid are reported in the same scatterplot (blue 
circles, brown circles, yellow circles and red circles, respectively). 
LEGEND – RVEDA: right ventricular end-diastolic area; PVR: pulmonary vascular resistance. 
Figure 2. Correlation between the changes in RVFAC and PVR at short-term follow-up:  ∆ RVFAC 
versus ∆ PVR (quadratic model: r2=0.40, p=0.0001, y=2.01+-0.22x-0.0007x2; linear model: 
r2=0.40, p=0.0001, y=-2.22-0.263x). Patients treated with oral monotherapy, prostanoid 
monotherapy, upfront oral combination and upfront oral plus prostanoid are reported in the same 
scatterplot (blue circles, brown circles, yellow circles and red circles, respectively). 
LEGEND – RVFAC: right ventricular fractional area change; PVR: pulmonary vascular resistance.  
Figure 3. RV morphology by echocardiographic evaluation, at diagnosis and after 6-month 
treatment, in an IPAH naïve patient treated with upfront combination therapy (parenteral prostanoid 
plus oral drug). A – Baseline evaluation: extreme RV dilation associated with LV compression; B – 
Six-month evaluation: significant reduction in RV size associated with LV decompression. 
LEGEND – RV: right ventricular; LV: left ventricular; IPAH: idiopathic pulmonary arterial 
hypertension. 
Figure 4. Changes in patients’ risk profile at baseline and follow-up, in each group of treatment 
strategy (Group 1, upfront combination oral plus prostanoid; Group 2, upfront oral combination; 
Group 3, oral monotherapy; Group 4, parenteral prostanoid monotherapy). The columns represent 
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the percentage of patients with low (green column), intermediate (yellow column) and high-risk 
profile (red column) at follow-up evaluation, based on their baseline risk profile (x-axis).  
Figure 5. The histogram shows the different patients’ percentage in each group of treatments 
(Group 1, upfront combination oral plus prostanoid, red column; Group 2, upfront oral combination, 
yellow column; Group 3, oral monotherapy, blue column; Group 4, parenteral prostanoid 
monotherapy, brown column) achieving the target-goals highlighted by guidelines (WHO I-II; 
6MWT >440 m; RAP < 8 mmHg; CI ( 2.5 l/min/m2; RA area <18 cm2; no PE).   
LEGEND – WHO: functional class; 6MWT: six-minute walk test; RAP: right atrial pressure; CI: 
cardiac index; RA area: right atrium area; PE: pericardial effusion. 
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  Upfront Therapy  Monotherapy  
 Group 1 
n. 27 
Group 2 
n.42 
Group 3 
n.69 
Group 4 
n.27 
p  
 
Age, years 53±18 55±14 54±13 54±15 NS 
Gender, F:M 18:9 26:16 42:27 16:11 NS 
Height, cm 163±9 164±11 165±10 166±9 NS 
Weight, Kg 68±14 72±15 71±18 68±13 NS 
Time symptoms-
diagnosis 
8.1±4.9 8.0±7.5 10.1±7.4 9.4±3.4 NS 
WHO 3.2±0.4 3.1±0.4 3.0±0.6 3.2±0.4 NS 
6MWT, m 306±88 314±104 321±103 322±78 NS 
Hemodynamics      
RAP, mmHg 10.4±2.2 9.4±4.7 9.1±4.5 9.7±3.6 NS 
mPAP, mmHg 54.4±11 52.5±9.6 54±13.3 55.4±11.7 NS 
CI, l/min/m2 2.1±0.5 2.2±0.6 2.2±0.5 2.2±0.5 NS 
PVR, WU 13.4±4.2 12.4±5.9 12.0±5.5 12.8±4.1 NS 
Echocardiography      
RVEDA, cm2 26.6±3.7 27.8±4.4 29.2±6.6 28.6±4.2 NS 
RVESA, cm2 19.0±2.6 20.0±3.6 20.4±5.8 19.9±3.9 NS 
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RVFAC, % 28.0±6.8 27.6±7.8 30.3±9.6 30.3±9.2 NS 
TAPSE, mm 15.6±2.4 15.8±4.1 16.4±4.0 16.1±3.5 NS 
RA Area, cm2  27.9±4.5 24.8±7.1 27.6±10 24.9±8.4 NS 
TR severe 6 (22.2%) 11 (26.2%) 16 (23.2%) 6 (22.2%)  NS 
LVEDA, cm2 20.6±3.2 20.4±6.7 21.0±6.4 20.1±5.4 NS 
LVESA, cm2 10.9±2.5 12.6±4.7 12.7±4.7 11.9±3.8 NS 
LV-EId 1.43±0.14 1.52±0.30 1.50±0.34 1.55±0.30 NS 
LV-EIs 1.60±0.27 1.68±0.35 1.74±0.43 1.62±0.26 NS 
LVEF, % 61.8±6.2 60.2±8.0 59.2±7.3 61.3±8.2 NS 
LA area, cm2 15.0±3.1 16.0±5.0 16.3±4.3 15.1±4.1 NS 
LV E wave PW, cm/s 0.6±0.2 0.8±0.4 0.6±0.3 0.7±0.4 NS 
LV A wave PW, cm/s 0.7±0.2 0.8±0.3 0.8±0.2 0.8±0.2 NS 
LV E/A 0.8±0.4 0.9±0.3 0.8±0.4 0.9±0.2 NS 
Pericardial effusion 11 (40.7%) 16 (38.1%) 25 (36.2%) 10 (37.0%) NS 
Bosentan   28 (40.6%)   
Ambrisentan   14 (20.3%)   
Sildenafil   18 (26.1%)   
Tadalafil   9 (13.0%)   
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Treprostinil s.c.    20 (74.1%)  
Epoprostenol i.v.    7 (25.9%)  
ERA + PDE5i      
Ambrisentan - Tadalfil  15 (21.7%)    
Ambrisentan - Sildenafil  4 (5.9%)    
Bosentan - Tadalafil  9 (13.0%)    
Bosentan - Sildenafil  7 (10.1%)    
Macitentan - Tadalafil  5 (7.2%)    
Macitentan - Sildenafil  2 (2.9%)    
Prostanoid + oral      
Treprostinil s.c.- Tadalafil 11 (15.9%)     
Treprostinil s.c.- 
Ambrisentan 
6 (8.7%)     
Treprostinil s.c. – Bosentan 3 (4.4%)     
Epoprostenol i.v. – Tadalafil 4 (5.9%)     
Epoprostenol i.v. - 
Bosentan 
2 (2.9%)     
Iloprost i. - Ambrisentan  1 (1.4%)     
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Table 1. Baseline characteristics of the upfront combination treated-group, divided in oral plus 
parenteral prostanoid (Group 1) and double oral combination (Group 2), compared with the two 
monotherapy matched cohorts, oral (Group 3) and prostanoids (Group 4).  
 
 
WHO: World Health Organization; 6MWT: non-encouraged 6-minute walk test; mPAP: mean pulmonary 
arterial pressure; RAP: mean right atrial pressure; CI: cardiac index; PVR: pulmonary vascular resistance; 
RA area: right atrium area; RVEDA: right ventricular end-diastolic area; RVESA: right ventricular end-systolic 
area; RVFAC: right ventricular fractional area change; TAPSE: tricupid anular plane systolic excursion; TR 
severe: severe tricuspid regurgitation; LV-EId: left ventricular end-diastolic eccentricity index; LV-EIs: left 
ventricular end-systolic eccentricity index; LVEDA: left ventricular end-diastolic area; LVESA: left ventricular 
end-systolic area; LVEF: left ventricular ejection fraction; LV E wave PW: pulsed wave left ventricular E 
wave; LV A wave PW: pulsed wave left ventricular A wave; ERA: endothelin receptor antagonist;  PDE5i: 
phosphodiesterase 5 inhibitor; s.c.: subcutaneous; i.v.: intravenous; i.: inhaled; Time symptoms-diagnosis: 
time from symptoms onset to diagnosis (months). 
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  Upfront Therapy Monotherapy Groups  
(155±65 days 
) 
 GROUP 1 GROUP 2 GROUP 3 3 
vs 
1 
3 
vs 
2 
1 
vs 
2 
 Basel
ine 
155±
65 
days 
 p Base
line 
155±
65 
days 
 p Basel
ine 
155±
65 
days 
 P p p p 
WHO 3.2±0
.4 
2.3±
0.5 
-
0.9±
0.4 
0.
00
0 
3.1±
0.4/  
2.2±
0.4 
-
0.9±
0.5 
0.
00
0 
3.0±0
.6 
2.5±
0.6 
-
0.4±
0.6 
0.
00
0 
0.
03
7 
0.
00
3 
N
S 
6MWT, m 306±
88 
408±
87 
101±
52 
0.
00
0 
314±
104  
363±
121 
56±5
3 
0.
00
0 
321±
103 
348±
123 
26±
48 
0.
00
0 
0.
00
1 
0.
00
7 
0.
00
1 
Hemodyn
amics 
               
RAP, 
mmHg 
10.4±
2.2 
6.1±
3.1 
-
4.1±
2.4 
0.
00
0 
9.5±
4.7 
7.2±
3.8 
-
2.4±
4.2 
0.
00
0 
9.1±4
.6 
7.9±
4.1 
-
1.1±
4.1 
0.
01
4 
0.
00
0 
N
S 
0.
01 
 
mPAP, 
mmHg 
54.4±
11 
38.4
±8.9 
-
15.6
±10.
8 
0.
00
0 
52.5
±9.6 
43±1
1 
-
10.4
±10.
8 
0.
00
0 
54±1
3.3 
51.3
±13.
2 
-
3.3±
5.3 
0.
00
0 
0.
00
0 
0.
00
1 
N
S 
CI, 
l/min/m
2
 
2.1±0
.5 
2.7±
0.2 
0.6±
0.5 
0.
00
0 
2.2±
0.6 
2.8±
0.6 
0.7±
0.6 
0.
00
0 
2.2±0
.5 
2.5±
0.5 
0.3±
0.3 
0.
00
0 
0.
00
2 
0.
00
4 
N
S 
PVR, UW 13.4±
4.2 
6.2±
2.4 
-
6.8±
2.8 
0.
00
0 
12.4
±5.9 
7.3±
3.0 
-
5.8±
4.5 
0.
00
0 
12.0±
5.5 
10.7
±5.5 
-
1.8±
2.5 
0.
00
0 
0.
00
0 
0.
00
1 
0.
04 
Echocard
iography 
               
RVEDA, 26.6± 20.0 -
6.8±
0.
00
27.8 23.5 -
4.3±
0.
00
29.0± 29.2 -
0.3±
N 0.
00
0.
00
0.
01
28 
 
cm
2 3.7 ±4.2 4.4 0 ±4.4 ±5.7 3.8 0 7.0 ±7.0 3.5 S 0 0 5 
RVESA, 
cm
2 
19.0±
2.6 
11.1
±2.7 
-
7.9±
3.4 
0.
00
0 
20.0
±3.6 
14.7
±4.5 
-
5.3±
3.5 
0.
00
0 
20.2 
±6.0 
20.4
±6 
-
0.1±
4.2 
N
S 
0.
00
0 
0.
00
0 
0.
00
1 
RVFAC, % 28.0±
6.8 
43.0
±7.7 
15.6
±5.2 
0.
00
0 
27.6
±7.8 
36.9
±10.
2 
9.2±
7.4 
0.
00
0 
30.4 
±9.6 
30.2
±9.2 
0.0±
7.7 
N
S 
0.
00
0 
0.
00
2 
0.
01
4 
TAPSE, 
mm 
15.6±
2.4 
22.2
±3.4 
6.3±
2.7 
0.
00
0 
16±4
.0 
18.9
±4.2 
3.1±
4.1 
0.
00
0 
16.4±
4.0 
17.4
±4.3 
0.6±
4.8 
0.
01
5 
0.
00
0 
0,
00
9 
0.
00
1 
RA Area, 
cm
2
  
27.9±
4.5 
20.1
±5.2 
-
7.4±
4.6 
0.
00
0 
24.8
±7.1 
20.9
±6.0 
-
2.6±
5.6 
0.
00
0 
27.6±
10 
27.1
±8.9 
-
0.4±
3.8 
N
S 
0.
00
0 
0.
00
0 
0.
00
1 
TR severe 6 
(22.2) 
1 
(3.7
%) 
 0.
00
1 
11 
(26.2
%) 
3 
(7.1
%) 
 0.
00
1 
16 
(23.2
%) 
13 
(19.1
%) 
 N
S 
0.
00
3 
0.
00
3 
N
S 
LVEDA, 
cm
2
 
20.6±
3.2 
21.6
±3.2 
1.0±
1.4 
0.
00
4 
20.4
±6.7 
21.8
±6.9 
1.4±
3.1 
0.
01
6 
21.0±
6.4 
21.2
±6.1 
0.1±
1.9 
N
S 
N
S 
N
S 
N
S 
LVESA, 
cm
2
 
10.9±
2.5 
11.3
±2.0 
0.5±
1.5 
N
S 
12.6
±4.7 
13.3
±5.7 
0.7±
2.4 
N
S 
12.7±
4.7 
12.9
±4.8 
0.3±
1.5 
N
S 
N
S 
N
S 
N
S 
LV-EId 1.43±
0.14 
1.13
±0.0
9 
-
0.3±
0.1 
0.
00
0 
1.52
±0.3
0 
1.26
±0.2
6 
-
0.18
±0.4
2 
0.
00
0 
1.50±
0.34 
1.49
±0.3
9 
-
0.01
±0.2 
N
S 
0.
00
0 
0.
00
2 
0.
02
7 
LV-EIs 1.60±
0.27 
1.20
±0.1
3 
-
0.4±
0,2 
 
0.
00
0 
1.68
±0.3
5 
1.34
±0.2
6 
-
0.24
±0.5
1 
0.
00
0 
1.74±
0.43 
1.68
±0.4
8 
-
0.16
±3.9 
0.
04
5 
0.
00
0 
0.
00
0 
0.
01
4 
LVEF, % 61.8±
6.2 
61.6
±5.8 
-
0.1±
2.5 
N
S 
60.2
±8.0 
62.6
±8.5 
2.4±
5.9 
N
S  
59.2±
7.3 
60.3
±7.2 
0.5±
5.1 
N
S 
N
S 
N
S 
N
S 
LA area, 
cm
2
 
15.0±
3.1 
15.2
±3.4 
0.0±
1.0 
N
S 
15.9
±5.0 
15.9
±4.7 
0.6±
2.4 
N
S 
16.3±
4.3 
16.2 
2±4.
3 
0.1±
3.0 
N
S 
N
S 
N
S 
N
S 
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LV E wave 
PW, cm/s 
0.62±
0.2 
0.76
±0.2 
0.13
±0.1 
0.
00
0 
0.75
± 0.4 
0.88
±0.4 
0.12
±0.2 
0.
01
1 
0.61±
0.3 
0.65
±0.3 
0.04
±0.2 
N
S 
0.
02 
0.
02 
N
S 
LV A wave 
PW, cm/s 
0.66±
0.2 
0.70
±0.1 
0.04
±0.1 
0.
01
5 
0.78
±0.3 
0.86
±0.2 
0.08
±0.2 
0.
04
8 
0.75±
0.2 
0.78
±0.2 
0.03
±0.1 
N
S 
N
S 
N
S 
N
S 
LV E/A 1.0±0
.4 
1.15
±0.4 
0.12
±0.2 
0.
01
3 
0.9±
0.3 
1.0±
0.3 
0.05
±0.3 
N
S 
0.82±
0.4 
0.82
±0.3 
0.0±
0.2 
N
S 
0.
03 
0.
03 
N
S 
Pericardial 
effusion 
11 
(40.7
%) 
1 
(3.7
%) 
 0.
00
1 
16 
(38.1
%) 
6 
(14.3
%) 
 0.
00
2 
25 
(36.2
%) 
22 
(31.9
%) 
 N
S 
0.
00
1 
0.
00
1 
0.
00
1 
 
Table 2. Changes in clinical, hemodynamic and echocardiographic parameters from baseline to 
short-term follow-up in Group1, 2 and 3. 
 
WHO: World Health Organization; 6MWT: non-encouraged 6-minute walk test; mPAP: mean pulmonary 
arterial pressure; RAP: mean right atrial pressure; CI: cardiac index; PVR: pulmonary vascular resistance; 
RA area: right atrium area; RVEDA: right ventricular end-diastolic area; RVESA: right ventricular end-systolic 
area; RVFAC: right ventricular fractional area change; TAPSE: tricupid anular plane systolic excursion; TR 
severe: severe tricuspid regurgitation; LV-EId: left ventricular end-diastolic eccentricity index; LV-EIs: left 
ventricular end-systolic eccentricity index; LVEDA: left ventricular end-diastolic area; LVESA: left ventricular 
end-systolic area; LVEF: left ventricular ejection fraction; LV E wave PW: pulsed wave left ventricular E 
wave; LV A wave PW: pulsed wave left ventricular A wave; ERA: endothelin receptor antagonist;  PDE5i: 
phosphodiesterase 5 inhibitor. 
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 GROUP 4 GROUPS 
 Baseline 155±65 days  p 1 vs 4 
p 
2 vs 4   
p 
3 vs 4 
p 
WHO 3.2±0.4 2.2±0.6 -0.9±0.4 0.000 NS NS 0.02 
6MWT, m 322±78 371±89 48±26 0.000 0.001 NS 0.004 
Hemodynamics        
RAP, mmHg 9.7±3.6 6.5±2.3 -3.3±3.9 0.000 NS NS 0.001 
mPAP, mmHg 55.4±11.7 43.8±8.6 -11.5±13 0.000 NS NS 0.000 
CI, l/min/m
2
 2.2±0.5 2.7±0.4 0.5±0.4 0.000 NS NS 0.002 
PVR, UW 12.8±4.1 7.4±3.2 -5.2±1.2 0.000 0.02 NS 0.001 
Echocardiography        
RVEDA, cm
2 28.6±4.2 23.4±4.2 -5.2±3.5 0.000 0.01 NS 0.000 
RVESA, cm
2 19.9±3.9 14.9±3.3 -5.8±3.7 0.000 0.001 NS 0.000 
RVFAC, % 30.3±9.2 36.3±9.5 6.0±6.1 0.000 0.01 NS 0.000 
TAPSE, mm 16.1±3.5 19.3±3.8 3.1±2.8 0.000 0.001 NS 0.000 
RA Area, cm
2
  24.9±8.4 21.5±7.5 -3.1±3.9 0.000 0.001 NS 0.000 
TR severe 6 (22.2%)  2 (8.7%)  0.004 NS NS 0.003 
LVEDA, cm
2
 20.1±5.4 20.1±5.3 0.04±0.5 NS NS NS NS 
LVESA, cm
2
 11.9±3.8 11.9±4.2 -0.02±0.7 NS NS NS NS 
31 
 
LV-EId 1.55±0.3 1.38±0.3 -0.11±0.3 0.000 0.01 NS 0.002 
LV-EIs 1.62±0.2 1.42±0.3 -0.13±0.3 0.000 0.01 NS NS 
LVEF, % 61.3±8.2 61.8±6.8 0.20±0.8 NS NS NS NS 
LA area, cm
2
 15.1±4 15.3±3.8 0.2±0.8 NS NS NS NS 
LV E wave PW, cm/s 0.7±0.4 0.7±0.4 0.05±0.1 NS 0.02 NS NS 
LV A wave PW, cm/s 0.8±0.2 0.8±0.2 0.03±0.1 NS NS NS NS 
LV E/A 0.9±0.2 0.8±0.2 0.07±0.2 NS 0.02 NS NS 
Pericardial effusion 10 (37.0%) 3 (11.1%)  0.001 0.001 NS 0.001 
Table 3. Changes in clinical, hemodynamic and echocardiographic parameters from baseline to 
short-term follow-up in Group 4. 
 
WHO: World Health Organization; 6MWT: non-encouraged 6-minute walk test; mPAP: mean pulmonary 
arterial pressure; RAP: mean right atrial pressure; CI: cardiac index; PVR: pulmonary vascular resistance; 
RA area: right atrium area; RVEDA: right ventricular end-diastolic area; RVESA: right ventricular end-systolic 
area; RVFAC: right ventricular fractional area change; TAPSE: tricupid anular plane systolic excursion; TR 
severe: severe tricuspid regurgitation; LV-EId: left ventricular end-diastolic eccentricity index; LV-EIs: left 
ventricular end-systolic eccentricity index; LVEDA: left ventricular end-diastolic area; LVESA: left ventricular 
end-systolic area; LVEF: left ventricular ejection fraction; LV E wave PW: pulsed wave left ventricular E 
wave; LV A wave PW: pulsed wave left ventricular A wave. 
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